Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.50 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28032601 | 0.88 | KMO (0.59) | KMOHDAC8RXRARXRBALDH1A1 | |
| SCHEMBL726087 | 0.86 | KMO (0.56) | KMOHDAC8RXRARXRBALDH1A1 | |
| SCHEMBL27623946 | 0.85 | MEN1 (0.55) | AURKAKMOPRKCICNR1SIRT2 | |
| SCHEMBL699008 | 0.84 | KMO (0.67) | KMOHDAC8RXRARXRBALDH1A1 | |
| SCHEMBL30698052 | 0.84 | KMO (0.67) | KMOHDAC8RXRARXRBALDH1A1 | |
| SCHEMBL207161 | 0.83 | KMO (0.71) | AURKAKMOPRKCINOTUMHDAC8 | |
| SCHEMBL29627221 | 0.83 | KMO (0.71) | AURKAKMOPRKCINOTUMHDAC8 | |
| Hydrogen Sulfide SCHEMBL27896825 | 0.82 | KMO (0.64) | KMOHDAC8RXRARXRBALDH1A1 | |
| SCHEMBL726544 | 0.82 | KMO (0.53) | KMOHDAC8RXRARXRBALDH1A1 | |
| SCHEMBL205967 | 0.82 | KMO (0.73) | KMOCNR1SIRT2ALDH1A1P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108299478-B | Cadmium-based metal organic framework material and preparation method and application thereof | 华南师范大学 | 2020-03-24 | — | — | CN | claimed |
| CN-109627450-B | 3D lanthanide metal coordination polymer and synthesis method and application thereof | 华南师范大学 | 2021-03-02 | — | — | CN | disclosed |
| CN-108299478-B | Cadmium-based metal organic framework material and preparation method and application thereof | 华南师范大学 | 2020-03-24 | — | — | CN | disclosed |
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | AURKA 2074/4885KMO 985/4885PRKCI 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.